Evergreen Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Evergreen Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$84.5K	Buy	17,429 +514	+3%	+$2.05K	﹤0.01%	1510
2026 Q1	$39.6K	Hold	16,915	–	–	﹤0.01%	1498
2025 Q4	$22.8K	Hold	16,915	–	–	﹤0.01%	1413
2025 Q3	$25.5K	Hold	16,915	–	–	﹤0.01%	1314
2025 Q2	$19.6K	Hold	16,915	–	–	﹤0.01%	1130
2025 Q1	$26.9K	Hold	16,915	–	–	﹤0.01%	1087
2024 Q4	$51.3K	Hold	16,915	–	–	﹤0.01%	1058
2024 Q3	$62.2K	Hold	16,915	–	–	﹤0.01%	991
2024 Q2	$69.2K	Sell	16,915 -98	-0.6%	-$1.09K	﹤0.01%	931
2024 Q1	$268K	Buy	17,013 +98	+0.6%	+$1.35K	0.01%	676
2023 Q4	$256K	Hold	16,915	–	–	0.01%	665
2023 Q3	$339K	Hold	16,915	–	–	0.01%	513
2023 Q2	$477K	Hold	16,915	–	–	0.02%	403
2023 Q1	$291K	Hold	16,915	–	–	0.01%	522
2022 Q4	$341K	Hold	16,915	–	–	0.02%	449
2022 Q3	$366K	Buy	+16,915	New	+$463K	0.02%	401

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Evergreen Capital Management's ZNTL Position: Q2 2026 in Review

Evergreen Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 3% in Q2 2026, buying an estimated $2.05K and bringing the position to 17,429 shares worth $84.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

Evergreen Capital Management first reported a position in ZNTL in Q3 2022 and has held it in 16 quarters since. The position peaked at $477K in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Evergreen Capital Management held 17,429 shares of Zentalis Pharmaceuticals worth $84.5K as of Q2 2026.
Evergreen Capital Management bought 514 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.05K.
Zentalis Pharmaceuticals made up ﹤0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #1510 holding.
Evergreen Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Evergreen Capital Management's Zentalis Pharmaceuticals position peaked at $477K in Q2 2023.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.